New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTGMCR, SYMC, CVE, VPHM, DUK, FTI, RPM, RAS, MXIM, CELG, PDH, CS, BSX, MLNX, CLFOn The Fly: Analyst Upgrade Summar
Today's noteworthy upgrades include: Boston Scientific (BSX) upgraded to Outperform from Neutral at Credit Suisse... Celgene (CELG) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Buy from Hold at Deutsche Bank... Credit Suisse (CS) upgraded to Outperform from Neutral at Exane BNP Paribas... Maxim Integrated (MXIM) upgraded to Outperform from Perform at Oppenheimer... Mellanox (MLNX) upgraded to Buy from Neutral at UBS... PetroLogistics (PDH) upgraded to Buy from Neutral at Citigroup... RAIT Financial (RAS) upgraded to Outperform from Market Perform at FBR Capital... RPM (RPM) upgraded to Perform from Underperform at Oppenheimer... ViroPharma (VPHM) upgraded to Buy from Neutral at BofA/Merrill... Symantec (SYMC) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Overweight from Equal Weight at Morgan Stanley... Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan... Green Mountain (GMCR) upgraded to Buy from Hold at Argus... Duke Energy (DUK) upgraded to Buy from Neutral at UBS.
News For BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 9, 2014
07:44 EDTCELGAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:46 EDTCELGCelgene presents POMALYST/IMNOVID Phase IIIb study results at ASH meeting
Celgene announced that results from the STRATUS trial, a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting. Pomalidomide is marketed as POMALYST in the United States and IMNOVID in the European Union. In the study, 599 patients with refractory, or relapsed and refractory, disease who had previously failed lenalidomide and bortezomib had been enrolled at the time of the data cutoff. The primary endpoint was safety, and key secondary endpoints included pomalidomide exposure, overall response rate, or ORR, duration of response, or DOR, progression-free survival, or PFS, overall survival, or OS, and cytogenetic analyses. Patients had a median five prior therapies. All patients received thromboprophylaxis with low-dose aspirin, low-molecular-weight heparin, or equivalent. At a median follow-up of 6.8 months with a median four cycles received, the median PFS and OS were 4.2 months and 11.9 months, respectively. The ORR was 35%, with 8% of patients achieving at least a very good partial response, or VGPR. The median DOR was 6.8 months. In patients refractory to prior lenalidomide or lenalidomide and bortezomib, similar PFS, OS, and ORR were achieved.
05:22 EDTCELGCelgene reports REVLIMID study data suggests improved response rates, PFS, OS
Subscribe for More Information
05:17 EDTCELGCelgene reports Vidaza Phase III study shows doubled overall survival times
Subscribe for More Information
December 8, 2014
14:06 EDTCELGCelgene reports luspatercept, sotatercept increased hemoglobin levels in trials
Subscribe for More Information
13:54 EDTCELGCelgene announces results from phase lll Revlimid study
Subscribe for More Information
12:35 EDTDUKDuke Energy receives approval from NCUC to build three solar facilities
Subscribe for More Information
10:42 EDTBSXOptions with increasing implied volatility
Subscribe for More Information
07:56 EDTCSRBS asks Credit Suisse, others for Coutts bids by Christmas, Reuters says
Subscribe for More Information
07:36 EDTCELGAgios announces Celgene to extend discovery phase of collaboration to April 2016
Agios Pharmaceuticals (AGIO) announced that Celgene (CELG) has elected to extend the period of its exclusivity for an additional year to April 2016 under the global strategic collaboration agreement. The two companies have been working together since April 2010 to discover, develop and commercialize disease-altering therapies in oncology arising from Agios' cancer metabolism research platform. The terms of the collaboration extension are consistent with previously agreed upon financial terms. As a result of the extension, Celgene will maintain its exclusive option to drug candidates that emerge from Agios' cancer metabolism research platform through April 2016. Agios will receive a $20M payment. Following this extension, the discovery portion of the collaboration will expire on April 14, 2016. Under the terms of the original agreement announced in April 2010, Agios leads research, preclinical and early development efforts through Phase 1, while Celgene receives an option to obtain exclusive rights either upon IND acceptance or at the end of Phase 1, to further development and commercialize medicines emerging from Agios' cancer metabolism research. Celgene would lead and fund global development and commercialization of some of these drugs, and Agios would retain development and commercialization rights for certain drugs in the United States. On all programs, Agios is eligible to receive up to $120M in milestone-based payments as well as royalties on any sales.
07:32 EDTMXIMRaymond James to hold a conference
Subscribe for More Information
07:28 EDTMLNXFBN Securities to hold a bus tour
Subscribe for More Information
07:17 EDTCELGCelgene price target raised to $131 from $120 at Cantor
Subscribe for More Information
05:53 EDTBSXStocks with implied volatility movement; BSX BMY
Subscribe for More Information
05:35 EDTCELGCelgene REVLIMID, low-dose dexamethasone increased PFS
Subscribe for More Information
December 7, 2014
18:31 EDTCSCredit Suisse assesses prime brokerage business, Reuters says
Subscribe for More Information
16:40 EDTCELGAgios announces new data from Ongoing Phase 1 trial of AG-221
Subscribe for More Information
14:10 EDTCELGAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:16 EDTCELGCelgene, Acceleron announced data from luspatercept phase 2 clinical trial
Subscribe for More Information
December 6, 2014
09:28 EDTCELGCelgene to hold an analyst and investor event
Analyst and Investor Event being held in conjunction with the American Society of Hematology's 56th Annual Meeting in San Francisco on December 7 at 11 pm. Webcast Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use